Work

Terapie a bersaglio molecolare e immunosopressori convenzionali nel trattamento dei disordini congeniti da immunodisregolazione: studio nazionale multicentrico

Year: 2024
Type: dissertation
Study design: Observational Study
Abstract: The inherited immune disorders (inborn errors of immunity-IEI) are extremely heterogeneous from both a pathogenetic and clinical point of view. In recent years, there has been a growing interest in the non-infectious manifestations of IEI, particularly those resulting from immunological dysregulation. The most recent classification of IEI, published in 2019 by the International Union of Immunological Societies (IUIS), includes a specific category of diseases called "immunodysregulation disorders", which includes 7 subclasses: familial hemophagocytic lymphohistiocytosis (HLH), HLH with hypopigmentation, regulatory T-cell disorders, autoimmune lymphoproliferative syndromes, IEI with autoimmunity with/without lymphoproliferation, immunodysregulation disorders with colitis, and EBV-related disorders. For most of these pathologies, the only definitive treatment currently available is hematopoietic stem cell transplantation (HSCT). A better understanding of the molecular and genetic bases of immunodysregulation disorders has led to the identification of new nosological entities and specific therapeutic targets for each clinical entity. Despite the progress in the treatment of immunodysregulation disorders, the number of patients treated with target therapies described in the literature remains limited; therefore, the knowledge of the efficacy and safety of therapies (both target-directed and HSCT) remains incomplete. There is a clear need to deepen the understanding of the efficacy and safety of conventional immunosuppressive therapies, target therapies, and HSCT in this broad and complex category of patients. Objectives. Identification of therapeutic strategies in patients with immunodysregulation disorders, including both conventional immunosuppressive drugs and small molecule inhibitors, and biological drugs, as well as the evaluation of the efficacy of these therapeutic approaches. Identifying the role of HSCT in these patients, with particular attention to the timing of intervention and the clinical outcome. Materials and methods. This is a multicenter retrospective study involving the Pediatric Immunology and Pediatric Oncology-Hematology referral centers belonging to the IPINET network (Italian Primary Immunodeficiency Network). Data collection was performed using an anonymized database, and we collected a sample of 100 units, including patients diagnosed with IEI due to immunodysregulation formulated according to the criteria of the International Union of Immunological Societies (IUIS) 2019 classification for inborn errors of immunity. This definition includes patients with a confirmed genetic defect in their immune system as well as those who have received a clinical diagnosis of the disease. Results. We initially divided the total number of patients based on the categories of IEI (Inborn Errors of Immunity) according to the 2019 classification by the International Union of Immunological Societies (IUIS). This data showed that the majority of the included patients belonged to the classification category of immune dysregulation disorders (53/120) or antibody defects (41/120). Within these categories, the most represented subgroups were autoimmune lymphoproliferative syndromes (22/120) and common variable immunodeficiency (21/120), respectively, for immune dysregulation disorders and antibody defects. We highlighted that patients with hematological dysregulation were the most prevalent in the sample (89/120). Of these, 77 out of 89 patients received pharmacological treatment. The on-demand drugs used, such as IVIG and corticosteroid therapy, showed total efficacy in more than 50% of the patients. Specifically, efficacy was 52% for patients treated with IVIG and 62% for those treated with corticosteroids. The most commonly used conventional immunosuppressants were sirolimus, mycophenolate mofetil, and rituximab, all of which showed efficacy greater than 50% across the seven therapeutic lines present in the database. In particular, conventional immunosuppressants were effective in treating ALPS and CVID diseases. We analyzed the molecularly targeted drugs used both in phenotypes with hematologic dysregulation and in complex phenotypes associated with organ dysregulation, noting that the various targeted drugs had partial and/or complete efficacy, but especially highlighting that the percentage of non-response to the drug was low. Conclusions. Congenital immune disorders are highly heterogeneous nosological entities, and in recent years, with the development of new technologies, several pathogenic genes have been identified, enabling the development of drugs targeting these molecular sites. In this study, we analyzed how molecularly targeted drugs, despite the complex phenotypes of the patients studied, showed no rate of inefficacy. Therefore, we can conclude that it is necessary to further research and discover new molecular alterations causing IEI, currently without a known genetic diagnosis, to develop new targeted drugs and improve patients' quality of life.
Institution: University of Pisa
Language: Italian
Subfield: Immunology
Open Access status: green
OpenAlex ID: W6987569959
Cites: 35
Cited by:
Related to: 10